

Special Issue

Host Immune Status and Proliferation of Cancers

Message from the Guest Editors

Stressful conditions and infectious complications after surgery compromise the host's immune status, which often induces the recurrence of tumors and raises the metastatic rate. Recent anti-cancer therapy using immune checkpoint inhibitors has enabled effective utilization of immune cells to stimulate an anti-tumor effect and keep the patients in a good condition, thereby leading to the improvement of cancer prognosis. Host immune status after surgery is also affected by several other frailty factors such as aging, nutritious condition, and underlying diseases. We are planning to host a Special Issue titled "Host immune status and proliferation of cancers" in which the following topics will be taken up with relation to cancer proliferation/progression or deterioration of host cancer-bearing conditions: (1) Infectious complications and cancer prognosis; (2) Immune checkpoint inhibitors and cancer therapy; (3) Frailty and cancer prognosis; (4) Any stress conditions related to cancer proliferation/progression. All contributors are welcome to submit a paper to this special issue.

Guest Editors

Prof. Dr. Nariyoshi Shinomiya

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa 359-8513, Saitama, Japan

Dr. Hironori Tsujimoto

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa 359-8513, Saitama, Japan

Deadline for manuscript submissions

closed (30 April 2022)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/65844

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).